Mirum Pharmaceuticals, Inc. Share Price & Technical Analysis
MIRM · $98.62 (-2.04%)
Healthcare / Biotechnology
$98.62
-2.04%
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille s…
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
2% return in May, -1% avg return in past 3 year May month.
26% return in 2026, 57% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 30% | -10% | 2% | 3% | 2% | – | – | – | – | – | – | – | 26% |
| 25 | 18% | -1% | -5% | -4% | 3% | 14% | 2% | 44% | -1% | 0% | 1% | 8% | 78% |
| 24 | -10% | 8% | -13% | 1% | -4% | 40% | 18% | 7% | -9% | -1% | 19% | -11% | 43% |
| 23 | 21% | 0% | 2% | 13% | -3% | -1% | 0% | 2% | 19% | -13% | 18% | -8% | 50% |
| 22 | 20% | 23% | -8% | 7% | 0% | -16% | 29% | 0% | -18% | 6% | -18% | 4% | 29% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Uptrend · Neutral
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases; Brelovitug, for the treatment of chronic HDV infection, which is in Phase 2 clinical trial; and MRM-3379, that is in Phase 2 clinical study for the treatment of FXS. The company has a collaboration agreement with the Shire International GmbH; License Agreement with Pfizer Inc.; Sanofi-Aventis Deutschland GmbH; Novartis Pharma AG; Lonza Ltd.; Enthorin Therapeutics, LLC and Dart Neuroscience LLC; Asset Purchase Agreement with Asklepion Pharmaceuticals, LLC; License and Manufacturing Agreement with LGM Pharma; and Asset Purchase Agreement with Travere Therapeutics, Inc. The company was incorporated in 2018 and is headquartered in Foster City, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$6.35B
P/E ratio
—
52W high
$115.0
52W low
$42.89
Volume
4,39,894
Beta
0.52
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Mirum Pharmaceuticals, Inc. share price today?
- Mirum Pharmaceuticals, Inc. (MIRM) last traded around $98.62 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does MIRM have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for MIRM. Download the app for real-time alerts.
- How can I analyze Mirum Pharmaceuticals, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.